TG Therapeutics

is a biopharmaceutical company focused on the development of
novel treatments for B-cell malignancies and autoimmune diseases.

Click for full image >>

For Investors

NASDAQ: TGTX

News & Events

12.3.18

TG Therapeutics Announces Follow-Up Data from the Triple Combo of U2 plus Pembrolizumab in Patients with Rel/Ref CLL and Richter's Transformation at the 60th Annual ASH Meeting

12.4.18

TG Therapeutics Announces Follow-Up Data from the Triple Combination of U2 plus Bendamustine in Patients with DLBCL and FL at the 60th Annual ASH Meeting

Quick Links